The 2024 American Academy of Dermatology (AAD) Annual Meeting

Treatment with upadacitinib, an oral selective Janus kinase inhibitor, led to greater proportions of days spent with improved nighttime itch and sleep disturbance experienced by patients with moderate-to-severe atopic dermatitis (AD), according to an integrated analysis of the phase III Measure Up 1 and 2 studies presented at AAD 2024.

Home-based phototherapy is equally effective as in-office treatment for plaque or guttate psoriasis regardless of skin type, providing a convenient first-line treatment option for patients, according to data from the Light Treatment Effectiveness (LITE) study.

Injections with polidocanol (10XB-101) help dissolve the pocket of excess fat under the chin, with a faster onset of action and fewer side effects relative to synthetic deoxycholic acid compound (ATX-101) injections, according to the results of a phase IIb study.

Use of Chat Generated Pretrained Transformer (ChatGPT), a free artificial intelligence (AI)-based natural language processing tool, to answer dermatologic questions falls short of expectations, according to a study presented at AAD 2024. Responses by doctors are still preferable to ChatGPT-generated answers.

Twice-daily application of delgocitinib cream, a topical pan-Janus kinase inhibitor, works for adults with moderate-to-severe chronic hand eczema (CHE) compared with a vehicle cream, according to the pooled analysis of the phase III DELTA-1 and -2 trials presented at AAD 2024.